Branded Legacy, Inc. (OTC: BLEG) announced the successful elimination of approximately $1 million in legacy convertible debt originating under prior management, following a comprehensive review of historical obligations by the company’s new leadership team under Dr. Jamie Forrest, PhD, MPH. The company said it negotiated highly favorable terms with legacy debt holders to retire the instruments, resulting in an immediate improvement to the balance sheet, a reduction in future dilution risk, and increased financial flexibility for shareholders.
Management added that it is continuing to work with OTC Markets Group to update the issuer profile and disclosures on OTCMarkets.com and is focused on completing remaining requirements to remove the Yield Sign, while maintaining a policy of clear, factual, and milestone-based communications.
Branded Legacy is a forward-thinking holdings company dedicated to pioneering solutions in addiction treatment and harm reduction. Through its subsidiary, BioLegacy Evaluative Group, and strategic collaborations with leading institutions like McMaster University and Stanford University, the company drives transformative research and innovation. With a state-of-the-art GMP manufacturing facility in Vancouver, Branded Legacy leverages advanced production capabilities to deliver cutting-edge products, positioning itself as a leader in addressing critical public health challenges.
This debt elimination marks a significant milestone for the company under its new leadership, signaling a commitment to financial discipline and shareholder value. The move is expected to enhance investor confidence and provide a stronger foundation for future growth initiatives.
